A Detroit Medical Center hospital has begun treating patients with the first gene therapy for beta-thalassemia, a rare blood ...

Life expectancy for people with sickle cell in the U.S. has increased to about 50 years, but some people with the disease still face stigma and other barriers in health care ...

He also believes there’s still too few of the therapies on the market to draw any sweeping conclusions on reasons for their ...

Screenings can be conducted before or during pregnancy and couples may be referred to the programme during obstetric visits ...

BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to ...

Chief Minister Sukhvinder Singh Sukhu reveals Rs 355 crore pending under Himcare, including dues to private hospitals, in the Himachal Pradesh Assembly.

Global Blood Transfusion Diagnostics Market is valued at approximately USD 4.6 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 4.9% over the forecast period ...

For those with $200 to spare that isn't being saved for emergencies, let's consider two healthcare stocks within that budget ...

CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” second quarter 2024 investor letter. A ...

We recently compiled a list of the 12 Best Biotech Stocks To Invest In According To Hedge Funds. In this article, we are ...